Government Affairs Consultant (Germany)
6-Month Contract | Part-Time Consultancy (2-3 Days Per Week)
Location: Germany. Berlin preferred; Baden-Württemberg, Bavaria, North Rhine-Westphalia also suitable. Regular travel to Berlin, Bonn and selected university-hospital/policy hubs expected.
What We're Seeking
Oxford Nanopore is seeking an experienced Government Affairs Consultant to lead our policy engagement and stakeholder strategy in Germany on a part-time consultancy basis. This is a unique opportunity for a well-connected health policy professional to help shape the environment for the adoption of innovative genomic technologies within one of Europe's most influential healthcare markets.
The successful consultant will bring deep knowledge of the German healthcare and policymaking landscape, with the ability to engage credibly across government, self-governance bodies, clinical networks, patient organisations and industry associations. Working closely with our Global and EMEA Government Affairs teams, you will help position Oxford Nanopore as a trusted partner in the development of genomic medicine, health-data infrastructure and future reimbursement pathways.
We are particularly interested in individuals who understand the intersection of healthcare policy, diagnostics, genomics and innovation, and who are motivated by the opportunity to support the integration of next-generation sequencing technologies into clinical practice across rare disease, oncology and pathogen genomics.
Key Responsibilities
- Strategy and positioning: Develop the Germany government affairs plan and policy narrative for nanopore sequencing in genomic medicine, health-data infrastructure, reimbursement and preparedness.
- Stakeholder engagement: Build compliant relationships with priority federal, self-governance, Länder, trade-association, clinical-network and patient stakeholders, including BfArM/genomDE/MV GenomSeq, G-BA/IQWiG and VDGH.
- Policy intelligence: Monitor § 64e SGB V, genomDE, GDNG/FDZ Gesundheit, EHDS, IVDR, ePA and reimbursement developments; summarise implications, risks and opportunities.
- Evidence and access: Support Market Access, Medical/Clinical Affairs, Regulatory and technical teams on evidence gaps, validation requirements and policy barriers in rare disease, oncology and pathogen genomics.
- External representation: Support agreed policy forums, association work, stakeholder briefs, meeting readouts, roundtables, consultation inputs and position papers, in conjunction with central Government Affairs team.
- Compliance and reporting: Maintain stakeholder maps, engagement trackers and monthly intelligence notes; ensure activities follow Oxford Nanopore policies, German transparency requirements and Legal/Compliance review.
Experience:
Essential- Native or fluent German speaker with strong English
- Significant experience in German health policy/government affairs
- Strong understanding of Germany’s healthcare system, including federal/Länder structure and key decision-making bodies
- Proven ability to credibly engage with public institutions, clinicians, and scientific stakeholders
- Experience in genomics, diagnostics, or precision medicine
- Familiarity with key frameworks (e.g. §64e SGB V, G-BA/IQWiG processes, genomDE, EHDS)
- Existing network across government, policy and to some extent university hospitals, research institutes, or relevant agencies
- Understanding of the wider EU policy landscape and the role of Brussels
Success Measures
- Evidence of ONT engagement within key policy and government stakeholders
- Development of a credible German political stakeholder network supporting ONT use cases
- Contribution to positioning ONT as a trusted partner in German genomics infrastructure
Why This Role Matters
Germany is an institution-led market where clinical adoption depends on validation, governance, and reimbursement systems rather than commercial access alone. This role is therefore critical to ensuring ONT is embedded within the structures that define long-term clinical scale.
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-Remote
#LI-RS1
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Skills Required
- Native or fluent German language skills
- Strong English language skills
- Significant experience in German health policy or government affairs
- Strong understanding of Germany's healthcare system, including federal and state structures and key decision-making bodies
- Proven ability to engage credibly with public institutions, clinicians, and scientific stakeholders
- Experience in genomics, diagnostics, or precision medicine
- Familiarity with German and European healthcare policy frameworks, including §64e SGB V, G-BA/IQWiG processes, genomDE, and EHDS
- Existing network across government, policy, university hospitals, research institutes, or relevant agencies
- Understanding of the wider EU policy landscape and Brussels institutions
Oxford Nanopore Technologies Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Oxford Nanopore Technologies and has not been reviewed or approved by Oxford Nanopore Technologies.
-
Fair & Transparent Compensation — Pay is considered good to above average across many roles, with employer-provided ranges visible for several U.S. commercial and applications positions and company materials emphasizing market‑competitive base pay. Commercial and some senior technical posts, particularly in the U.S., are positioned as competitive and often paired with strong variable components.
-
Equity Value & Accessibility — All‑employee share plans in the UK and a U.S. employee stock purchase plan indicate broad access to equity as part of total reward. Company communications highlight attractive bonus and share plans that add meaningful upside beyond base pay.
-
Healthcare Strength — U.S. roles indicate strong health insurance and core protections, while official materials and country overviews reference private medical coverage and wellbeing support. These elements position the health package as a notable strength alongside cash compensation.
Oxford Nanopore Technologies Insights
What We Do
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
